Catch it Early. Make a Difference
Did you know that 10% of all dogs presented to primary care veterinarians suffer from heart disease? Usually, they’re affected by one of two conditions—myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM)—both of which may progress to congestive heart failure (CHF). As dogs age, their risk increases, but there are treatments that can help. Because MMVD can develop gradually with no visible signs early on, regular veterinary checkups and heart screenings play an important role in early detection and care.
Which Dogs Are at Risk for MMVD?
Myxomatous mitral valve disease (MMVD) is the most common heart disease in dogs and is seen most often in small-breed dogs over 5 years of age, particularly those weighing under 40 pounds. Any dog can develop heart disease, but some breeds may be at increased risk, including Cavalier King Charles Spaniel, Dachshund, Chihuahua, Maltese, Fox Terrier, Poodle, Papillon, and Miniature Schnauzer.
Give Them More Life to Love
Early-Stage Treatment
VETMEDIN® Chewable Tablets and VETMEDIN® Solution are the only medications approved by the FDA to delay the onset of congestive heart failure in dogs with Stage B2 MMVD. When heart failure is delayed in dogs with Stage B2 MMVD, VETMEDIN® gives your dog more symptom-free days.
Later-Stage Treatment
For dogs that have progressed into heart failure, treatment with VETMEDIN® Chewable Tablets and VETMEDIN® Solution has been demonstrated to extend survival time and improve quality of life.
One Treatment, Two Options
VETMEDIN® is available as both a liquid solution and chewable tablets, so you can give your dog just the right dose in a formulation that works for them.
VETMEDIN® Solution
The only brand to offer an oral solution that's flavorless for dogs who prefer a liquid medication.
VETMEDIN® Chewable Tablets
Beef-flavored and half-scored for dogs who prefer chews.
IMPORTANT SAFETY INFORMATION:
VETMEDIN® (pimobendan) Chewable Tablets and VETMEDIN® Solution (pimobendan oral solution) are for use only in dogs with Stage B2 preclinical myxomatous mitral valve disease (MMVD) or congestive heart failure (CHF) due to clinical MMVD or dilated cardiomyopathy (DCM). The most common non-cardiac adverse reactions reported in field studies, were poor appetite, lethargy, diarrhea, shortness of breath, vomiting, musculoskeletal pain, ataxia, and lack of muscle control and coordination. For full prescribing information, talk to your vet, or call 888-637-4251.
REFERENCES:
¹ Keene BW, Atkins CE, Bonagura JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019;33:1127-1140. https://doi.org/10.1111/jvim.15488
VETMEDIN® and the VETMEDIN Logo® are registered trademarks of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2026 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0653-2026-C